

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	10/680,734; Confirmation 5299
--------------------	-------------------------------

Filing Date	10/8/2003
--------------------	------------------

<i>First Named Inventor</i>	Goldenberg
-----------------------------	------------

Art Unit	1643
-----------------	-------------

Examiner Name | Lynn Anne Bristol

Attorney Docket Number	329241
-------------------------------	---------------

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
LAB	7	WO 92/01059	1/23/1992	Adair		
	8	EP 0 323 805 A3	7/12/1989	Buchegger		
	9	EP 0 323 806 A1	7/12/1989	Hardman		
	10	EP 0 239 400 A2	9/30/1987	Winter		
	11	WO 92/11018	7/9/1992	Queen		
	12	JP 02154696 A	6/14/1990	Hardman		
	13	JP 5-502587	5/13/1993	Adair		
	14	WO 91/01990	2/21/1991	Shively		
	15	WO 95/15769	6/15/1995	Hansen		

**Examiner
Signature**

/Lynn Bristol/

Date
Considered

09/28/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/680,734; Confirmation 5299
Filing Date	10/8/2003
First Named Inventor	Goldenberg
Art Unit	1643
Examiner Name	Bristol
Attorney Docket Number	329241

(Use as many sheets as necessary)

Sheet	3	of	4
-------	---	----	---

[illegible][illegible]

09/28/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number	10/680,734; Confirmation 5299
Filing Date	10/8/2003
First Named Inventor	Goldenberg
Art Unit	1643
Examiner Name	Bristol
Attorney Docket Number	329241

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAB	19	PRIMUS, F. JAMES, et al. "Immunological Heterogeneity of Carcinoembryonic Antigen: Antigenic Determinants on Carcinoembryonic Antigen Distinguished by Monoclonal Antibodies" Cancer Research 43, 686-692, February 1983 pgs. 686-692	
	~~20~~	~~HANSEN, HANS J. "Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen" Cancer, 71(11):3478-85, Jan. 1993, pgs. 3478-3485~~	
LAB	21	LOSMAN, MICHELE J., "Mimicry of a Carcinoembryonic Antigen Epitope by a Rat Monoclonal Anti-Idiotypic Antibody," Int. J. Cancer: 56, 580-584 (1994)	
	22	SHARKEY, ROBERT M., et al., "Clinical Evaluation of Tumor Targeting with a High-Affinity, Anticarcinoembryonic-Antigen-Specific, Murine Monoclonal Antibody, MN-14" Cancer 71(6):2082-2096 (1993)	
	23	RIECHMANN, Lutz, et al., "Reshaping Human Antibodies for Therapy" Nature Vol. 332 24 March 1988 pgs. 323-327	
	24	QUEEN, CARY, et al., "A Humanized Antibody that binds to the interleukin 2 receptor" Proc. Natl. Acad. Sci. USA Vol. 86, pp. 10029-10033, December 1989	
	25	BLUMENTAL, ROSALYN D., et al. "Targeted Therapy of Athymic Mice Bearing GW-39 Human Colonic Cancer Micrometastases with 131I-labeled Monoclonal Antibodies" Cancer Research 52, 6036-6044, November 1, 1992	
	26	VERHOEYEN, et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" Science, Vol 239, 9/29/1987, pgs. 1534-1536	
	27	SHARKEY, ROBERT M., "Comparison of Tumor Targeting in Nude Mice by Murine Monoclonal Antibodies Directed against Different Human Colorectal Cancer Antigens" Cancer Research (Suppl.) 50, 828s-834s, February 1, 1990	
	28	MUYLDERMANS, S., et al., "Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains" Protein Engineering Vol. 7 No. 9 pp. 1129-1135, 1994	
	29	STEIN, RHOMA, et al., "Combining Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Carcinoma" CANCER Volume 94, No. 1, January 1, 2002, pp. 51-61	

Examiner
Signature

/Lynn Bristol/

Date
Considered

09/28/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	10/680,734; Confirmation 5299
Filing Date	10/8/2003
First Named Inventor	Goldenberg
Art Unit	1643
Examiner Name	Lynn Anne Bristol
Attorney Docket Number	329241

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAB	30	JUWEID, MALIK E., "Phase I/II Trial of 131I-MN-14 F(ab)2 Anti-Carcinoembryonic Antigen Monoclonal Antibody in the Treatment of Patients with Metastatic Medullary Thyroid Carcinoma" Cancer Vol 85, No. 8 April 15, 1999, pp. 1828-1842	
	31	JUWEID, MALIK E. et al., "Radioimmunotherapy of Patients with Small-Volume Tumors Using Iodine-131-Labeled Anti-CEA Monoclonal Antibody NP-4 F(ab)2" The Journal of Nuclear Medicine, Vol 37, No. 9, September 1996, pp. 1504-1510	
	32	SHARKEY, Robert M., et al., "Evaluation of a Complementarity-Determining Region-Grafted (Humanized) Anti-Carcinoembryonic Antigen Monoclonal Antibody in Preclinical and Clinical Studies" Cancer Research Suppl. 155, December 1, 1998, pp 5935s-5945s	
	33	JUWEID, MALIK, et al., "Radioimmunotherapy of Medullary Thyroid Cancer with Iodine-131-Labeled Anti-CEA Antibodies" The Journal of Nuclear Medicine, Vol 37, No. 6, June 1996 pp. 905-911	
	34	STEIN, RHONA, et al., "A Humanized monoclonal antibody to carcinoembryonic antigen, labeluzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy" Mol. Cancer Ther 2004;3(12), December 2004, pp. 1559-1564	

Examiner
Signature

/Lynn Bristol/

Date
Considered

09/28/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.